| dc.contributor.author | Cloete, Ruben | |
| dc.contributor.author | Mikasi, Sello Given | |
| dc.contributor.author | Ikomey, George Mondinde | |
| dc.date.accessioned | 2021-01-08T09:21:35Z | |
| dc.date.available | 2021-01-08T09:21:35Z | |
| dc.date.issued | 2020 | |
| dc.identifier.citation | Cloete, R. et al. (2020). HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy. South African Medical Journal, 110(9), 827 | en_US |
| dc.identifier.issn | 2078-5135 | |
| dc.identifier.uri | 10.7196/SAMJ.2020.v110i9.14848 | |
| dc.identifier.uri | http://hdl.handle.net/10566/5617 | |
| dc.description.abstract | : The integrase (IN) strand-transfer inhibitor (InSTI)
dolutegravir (DTG) is now recommended by the World Health
Organization as part of salvage and/or first-line combination
antiretroviral therapy (cART).[1] DTG has a high genetic barrier
against developing resistance and is effective against all strains
that previously exhibited resistance-associated mutations (RAMs)
against other cART regimens.[2] Recommendations to use DTG were
delayed owing to preliminary findings from Botswana that indicated
potential safety concerns in pregnancy, with a small increased risk of
neural tube defects.[3] Studies that investigated the safety and efficacy
of DTG now support its use in all populations, including pregnant
women and those of childbearing potential | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | SAMA | en_US |
| dc.subject | HIV-1 | en_US |
| dc.subject | Africa | en_US |
| dc.subject | Antiretroviral therapy | en_US |
| dc.subject | Drug safety | en_US |
| dc.subject | Pregnant women | en_US |
| dc.title | HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy | en_US |
| dc.type | Article | en_US |
